头孢唑林预防性抗生素与肩关节置换术后假体周围感染率低于非头孢唑林方案相关
该研究基于单中心2000至2019年7713例初次肩关节置换术数据,比较围手术期抗生素选择与假体周围感染(PJI)的关系。头孢唑林组PJI风险较非头孢唑林组降低69%,痤疮丙酸杆菌PJI风险降低78%;万古霉素和克林霉素组PJI风险均升高。
要点
- 头孢唑林组全因PJI风险较非头孢唑林组降低69%,痤疮丙酸杆菌PJI风险降低78%(p<0.001)。
- 万古霉素组全因PJI的HR为2.32(95%CI 1.22至4.40;p=0.010),痤疮丙酸杆菌PJI的HR为2.94(95%CI 1.12至7.49;p=0.028)。
- 克林霉素组全因PJI的HR为5.07(95%CI 2.83至9.05;p<0.001),痤疮丙酸杆菌PJI的HR为8.01(95%CI 3.63至17.42;p<0.001)。
核心结论
- 在初次肩关节置换术中,头孢唑林给药与非头孢唑林替代方案(包括万古霉素和克林霉素)相比,PJI发生率显著更低。
- 这些风险差异在所有感染病原体中均观察到,当痤疮丙酸杆菌为感染细菌时可能被认为更大。
研究设计与样本
- 研究为单中心回顾性分析,纳入2000至2019年所有初次肩关节置换类型(半肩关节置换、解剖型全肩关节置换、反式肩关节置换),适应症为择期和创伤,具备围手术期抗生素数据且最低随访2年。
- 共纳入7713例肩关节置换术,采用多变量分析确定给药抗生素与PJI发生之间的关联。
主要发现
- 在7713例肩关节置换术中,头孢唑林用于6879例(89.2%),非头孢唑林抗生素用于834例(10.8%),包括万古霉素465例(6.0%)、克林霉素345例(4.5%)和替代方案24例(0.31%)。
- 101例肩关节置换术发生PJI(1.3%),痤疮丙酸杆菌为最常见病原体(44例[43.6%])。
- 头孢唑林组无PJI生存率高于非头孢唑林组,1个月时无PJI生存率高出0.91%,1年时高出1.4%,15年时高出2.7%(p<0.001)。
- 头孢唑林给药与非头孢唑林给药相比,全因PJI风险降低69%,痤疮丙酸杆菌PJI风险降低78%(p<0.001)。
- 万古霉素组全因PJI的HR为2.32(95%CI 1.22至4.40;p=0.010),痤疮丙酸杆菌PJI的HR为2.94(95%CI 1.12至7.49;p=0.028);克林霉素组全因PJI的HR为5.07(95%CI 2.83至9.05;p<0.001),痤疮丙酸杆菌PJI的HR为8.01(95%CI 3.63至17.42;p<0.001)。
关键数值与推荐
- 头孢唑林组全因PJI风险降低69%,痤疮丙酸杆菌PJI风险降低78%(p<0.001)。
- 万古霉素组全因PJI的HR为2.32(95%CI 1.22至4.40;p=0.010),痤疮丙酸杆菌PJI的HR为2.94(95%CI 1.12至7.49;p=0.028)。
- 克林霉素组全因PJI的HR为5.07(95%CI 2.83至9.05;p<0.001),痤疮丙酸杆菌PJI的HR为8.01(95%CI 3.63至17.42;p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although prophylactic antibiotics are considered the standard of care, data with regard to the comparative efficacy of specific antibiotics in the prevention of periprosthetic joint infection (PJI) have remained limited. This study evaluated whether perioperative antibiotic choice affects rates of PJI development in shoulder arthroplasty. METHODS: From 2000 to 2019, all primary shoulder arthroplasty types (hemiarthroplasty, anatomic total shoulder arthroplasty, reverse shoulder arthroplasty) performed for elective and trauma indications with perioperative antibiotic data and a minimum follow-up of 2 years were identified from a single institution. Demographic characteristics, PJI risk factors, and PJI-free survivorship data were retrieved. Multivariable analyses were conducted to determine the association between the antibiotic administered and the development of PJI. RESULTS: Of 7,713 shoulder arthroplasties, cefazolin was administered in 6,879 procedures (89.2%) and non-cefazolin antibiotics consisting of vancomycin (465 procedures [6.0%]), clindamycin (345 procedures [4.5%]), and alternative regimens (24 procedures [0.31%]) were administered in 834 procedures (10.8%). PJIs occurred in 101 shoulder arthroplasties (1.3%), with Cutibacterium acnes as the most common pathogen (44 procedures [43.6%]). PJI-free survivorship was greater in shoulder arthroplasties in which cefazolin was administered compared with those in which non-cefazolin antibiotics were administered, with 0.91% greater survival free of PJI at 1 month, 1.4% at 1 year, and 2.7% at 15 years (p < 0.001). Cefazolin administration, compared with non-cefazolin administration, was associated with a 69% reduction in all-cause PJI risk and a 78% reduction in C. acnes PJI risk (p < 0.001). A higher risk of PJI for both groups was observed with vancomycin; the hazard ratio [HR] was 2.32 (95% confidence interval [CI], 1.22 to 4.40; p = 0.010) for all-cause PJI and 2.94 (95% CI, 1.12 to 7.49; p = 0.028) for C. acnes PJI. A higher risk of PJI was also observed for both groups for clindamycin; the HR was 5.07 (95% CI, 2.83 to 9.05; p < 0.001) for all-cause PJI and 8.01 (95% CI, 3.63 to 17.42; p < 0.001) for C. acnes PJI. CONCLUSIONS: In primary shoulder arthroplasty, cefazolin administration was associated with a significantly lower rate of PJI compared with non-cefazolin alternatives, including both vancomycin and clindamycin. These risk discrepancies were observed across all infectious pathogens and may be considered even greater when C. acnes was the infecting bacterium. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Marigi EM, Bartels DW, Yoon JH, et al. Antibiotic Prophylaxis with Cefazolin Is Associated with Lower Shoulder Periprosthetic Joint Infection Rates Than Non-Cefazolin Alternatives. J Bone Joint Surg Am. 2022. PMID: 35188900. doi:10.2106/JBJS.21.00445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。